FDA
-
-
-
-
-
-
-
MoonLake receives FDA alignment on sonelokimab BLA submission plans
-
-
-
-
-
-
-
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
-
-
-
-
-
-
-
Moonlake Immunotherapeutics (MLTX) PT Raised to $45 at Clear Street
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
-
-
-
-
-
-
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
-
-
-
-
-
-
-
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
-
328,460 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

